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Supplemental methods section 
 
Computational analysis of steroid metabolite excretion (supplementary material) 
For computational steroid excretion data analysis, we employed a recently developed variant 
of Learning Vector Quantization (LVQ) [1], Generalized Matrix Relevance LVQ (GMLVQ) [2, 3], 
For GMLVQ experiments, all numerical steroid excretion values were log-transformed and 
subsequently normalized by subtracting the respective mean values obtained in healthy controls with a 
similar age and sex distribution (n=88) and dividing by the corresponding standard deviations. This 
yielded 32 log-transformed steroid excretion values for each patient, expressed on a scale set by the 
control group. The vectors of log-transformed excretion values (rescaled with respect to the controls) 
labeled with the corresponding class membership, i.e. either ACC or ACA, served as input for the 
machine learning system.   
 For evaluation of the performance of the trained system, we split the ACC and ACA data into 
a training and test set, respectively, with 90% of the data from each class used in the training process 
to determine prototypes and relevance matrix. The remaining 10% served as a test set, which was 
used to quantify the true positive rate, i.e. the fraction of ACC test data classified correctly as ACC, 
and the false positive rate, i.e. the fraction of ACA test data misclassified by the system as ACC. In 
order to suppress the influence of possible lucky or unlucky draws of the test set on the performance 
of the system, we repeated the procedure for 1000 randomized training/test data set compositions. As 
an additional preprocessing step, we applied a z-score transformation in each training process, such 
that for all markers the mean of the transformed excretion over the training set was zero and the 
corresponding variance was one. We employed a single prototype per class. Initial values for the 
prototypes were determined from the class conditional means of a random selection of training data. 
The relevance matrix was initially set as the identity, i.e. all steroids equally important and pair-wise 
relevance being zero. 
 Subsequently, we obtained the full Receiver Operating Characteristics (ROC) of the classifier, 
generated by varying the threshold generalized distance margin separating the two classes, and 
computed the area under curve (AUC). The mean ROC and standard deviations were calculated using 
threshold averaging, as described in [4].  
We have applied the GMLVQ machine learning analysis to the complete panel of 32 steroid 
markers. In addition, we studied the selection of discriminant features in GMLVQ:  In each training 
run we determined the subsets of the most relevant three or nine steroids from the obtained relevance 
matrix. The GMLVQ training process was then repeated, restricting the system to the use of the 
individually selected subsets of steroids. The resulting mean ROC curves quantify the achievable 
classification performance when using reduced panels of three or nine steroids selected by GMLVQ.    
 For comparison, we also employed statistical modeling techniques, Fisher Linear 
Discriminant Analysis (LDA) and a standard implementation of logistic regression (27). Logistic 
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Regression was implemented using the NAG® library routine G02GB (Numerical Algorithms Group, 
Oxford, UK), for LDA we employed the implementation in van der Maaten’s MATLAB® Toolbox for 
dimensionality reduction.   
For a small number of data points, the excretion values were found to be zero within the 
sensitivity of the GC/MS analysis; for log-transformation and machine learning analysis, these values 
were set to 10-10. It was verified that the choice of this correction parameter did not affect the 
classification. While steroid data in ACA patients (n=102) displayed no missing values, the available 
steroid excretion data for ACC patients (n=45) contained a total of 3.9% (56 out of 1440) missing 
steroid excretion values. For the LVQ analysis, missing values were ignored when comparing 
distances of a particular feature vector from different prototypes. For LDA and logistic regression 
analyses we replaced missing values by class conditional means, which should theoretically give a 
performance advantage to these two methods in comparison to GMLVQ.   
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Suppl. Table 1. Steroids and steroid metabolites analyzed in a single diagnostic run by gas 
chromatography/mass spectrometry (GC/MS).  
 




























DHEA + DHEAS 
5 5-PT Pregnenetriol 5-pregnene-3β,17, 20α-
triol 
17-hydroxypregnenolone 
6 5-PD Pregnenediol 5-pregnene-3β, 20α-diol 
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Glucocorticoid precursor metabolites 
 
14 PD Pregnanediol 5β-pregnane-3α, 20a-
diol 
progesterone  










17 PT Pregnanetriol 5β-pregnane-3α, 17α, 
20α-triol 
17-hydroxyprogesterone 












20 F Cortisol 4-pregnene-11β, 17, 21-
triol-3, 20-dione 
cortisol 
21 6β-OH-F 6β-hydroxy-cortisol 4-pregnene-6β, 11β, 17, 
21-tetrol-3, 20-dione 
cortisol 
22 THF Tetrahydrocortisol 5β-pregnane-3α, 11β, 
17, 21-tetrol-20-one 
cortisol 
23 5α-THF 5α-tetrahydrocortisol 5α-pregnane-3α, 11β, 
17, 21-tetrol-20-one 
cortisol 
24 α-cortol α-cortol 5β-pregnan-3α, 11β, 17, 
20α, 21-pentol 
cortisol 













28 E Cortisone  4-pregnene-17α, 21-diol-
3, 11, 20-trione 
cortisone 
29 THE Tetrahydrocortisone 5β-pregnene-3α, 17, 21-
triol-11, 20-dione 
cortisone 
30 α-cortolone α-cortolone 5β-pregnane-3α, 17, 
20α, 21-tetrol-11-one 
cortisone 
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Suppl. Table 2. Urinary excretion of steroid metabolites (median (interquartile range, IQR)) in healthy 
controls, patients with adrenocortical adenomas (ACA), and adrenocortical carcinoma patients (ACC).  
Steroids are numbered as in Fig. 1. Statistical analysis was performed employing Kruskal-Wallis 



















































































































     
Supplemental Appendix                                      Arlt et al.  Steroidobolomics in adrenal tumors 
6 
 










































































































































Supplemental Appendix                                      Arlt et al.  Steroidobolomics in adrenal tumors 
7 
 
































































































































* Comparison of Controls vs. ACA and ACC, respectively  
† Comparison of ACA vs. ACC 
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Suupl. Table 3. Urinary excretion of steroid metabolites by steroid subclass (median (interquartile range, IQR)) in ACA and ACC patients with or without evidence of 
hormone excess (according to the results of the routine biochemistry, see methods section for a detailed description) and in healthy controls. 

























































































































* comparison to healthy controls 
 †comparison between patient subgroups with and without evidence of hormone excess 




Suppl. Fig. 1 
Heat map showing individual excretion value for the 32 steroid metabolites in the 102 ACA and 45 
ACC patients. The color code represents the log-transformed steroid excretion values that were 
normalized to the healthy controls (n=88) by subtracting the respective mean values obtained in the 
controls and dividing by the corresponding standard deviation.  
 
